ライフサイエンスコーパス: invasive candidiasis

1 n percent of the target population will have invasive candidiasis.

2 treatment regimen may improve the outcome of invasive candidiasis.

3 a promising candidate for the prevention of invasive candidiasis.

4 were independently significant predictors of invasive candidiasis.

5 ntibodies, remain nonetheless susceptible to invasive candidiasis.

6 ol measurement may help to promptly diagnose invasive candidiasis.

7 in B and itraconazole were studied in murine invasive candidiasis.

8 Candida albicans causes severe invasive candidiasis.

9 e epithelial infections and life-threatening invasive candidiasis.

10 m superficial infections to life-threatening invasive candidiasis.

11 risk of invasive candidiasis and death after invasive candidiasis.

12 variables could be pooled across groups for invasive candidiasis.

13 to a controllable iatrogenic risk factor for invasive candidiasis.

14 elopment for the treatment of candidemia and invasive candidiasis.

15 nt of this class of antifungal drug to treat invasive candidiasis.

16 rocess of critical importance in controlling invasive candidiasis.

17 caspofungin in patients with candidaemia and invasive candidiasis.

18 ION: The primary outcomes were mortality and invasive candidiasis.

19 n treatment and prevention of candidemia and invasive candidiasis.

20 nts died, and 22 (1.5%) exhibited documented invasive candidiasis.

21 y treatment and prevention of candidemia and invasive candidiasis.

22 potential as biomarkers for anticipation of invasive candidiasis.

23 opment of a useful tool for the diagnosis of invasive candidiasis.

24 oint was hospital mortality or occurrence of invasive candidiasis.

25 da albicans reigning as the leading cause of invasive candidiasis.

26 o culture conversion in patients with proven invasive candidiasis.

27 lower incidence of the composite of death or invasive candidiasis.

28 rulence of C. glabrata in the mouse model of invasive candidiasis.

29 ) immunity underlie deep dermatophytosis and invasive candidiasis.

30 ary treatment of patients with candidemia or invasive candidiasis.

31 eveloped and approved for treatment of human invasive candidiasis.

32 persistent, although relatively low rate of invasive candidiasis.

33 s are being used increasingly as therapy for invasive candidiasis.

34 ninferior to fluconazole in the treatment of invasive candidiasis.

35 blind, noninferiority trial of treatment for invasive candidiasis.

36 zole to caspofungin for primary treatment of invasive candidiasis.

37 in is being used increasingly as therapy for invasive candidiasis.

38 to be efficacious in treating candidemia and invasive candidiasis.

39 sed with proven/probable IFIs, predominantly invasive candidiasis (46.8%).

40 Invasive candidiasis affects 1.6 million people annually

41 of invasive fungal infections, particularly invasive candidiasis, after liver transplantation is str

42 Additional risk factors for invasive candidiasis and aspergillosis may be unique to

43 We present a case report of invasive candidiasis and candidemia due to a Candida gla

44 ng-term follow-up and a detailed analysis of invasive candidiasis and candidiasis-related death in 30

45 cs were associated with an increased risk of invasive candidiasis and death after invasive candidiasi

46 nt, tests will also be useful for ruling out invasive candidiasis and discontinuing unnecessary antif

47 nts many challenges, which are different for invasive candidiasis and for invasive aspergillosis.

48 lopment for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive

49 rtality from 44.0% to 30.4% in patients with invasive candidiasis and from 22.4% to 21.0% in the over

50 Candida parapsilosis is a common cause of invasive candidiasis and has been classified as a high-p

51 h immunology to advance our understanding of invasive candidiasis and human fungal disease.

52 rophylactic fluconazole reduces the rates of invasive candidiasis and/or colonization of extremely-lo

53 , 91%, and 96% of patients were free of IFD, invasive candidiasis, and invasive aspergillosis at 1 ye

54 of beta-d-glucan assays in the diagnosis of invasive candidiasis, and the application of serology an

55 agnosis of invasive pulmonary aspergillosis, invasive candidiasis, and the common endemic mycoses was

56 m agents, antifungals predominantly used for invasive candidiasis, antibacterial agents posing the hi

57 As an example, in the treatment of invasive candidiasis, antifungal therapy with intravenou

58 Signs and symptoms of invasive candidiasis are non-specific; candidaemia is th

59 ical treatment based on surrogate markers of invasive candidiasis are warranted.

60 th Staphylococcus aureus bacteremia also had invasive candidiasis, based on histological findings in

61 e human gut is considered a prerequisite for invasive candidiasis, but our understanding of gut bacte

62 oint was the incidence of proven or probable invasive candidiasis by EORTC/MSG criteria in patients w

63 Blood cultures are limited for diagnosing invasive candidiasis by poor sensitivity and slow turn-a

64 Although a rare cause of invasive candidiasis, Candida guilliermondii has been re

65 osis, and C. krusei) account for over 95% of invasive candidiasis cases.

66 Seven cases of invasive candidiasis caused by C. glabrata occurred in H

67 The prevalence of invasive candidiasis caused by non-albicans Candida spec

68 Despite current antifungal therapy, invasive candidiasis causes >40% mortality in immunocomp

69 uman fungal pathogen Candida albicans causes invasive candidiasis, characterized by fatal organ failu

70 ents with suspected IFI was the diagnosis of invasive candidiasis confirmed.

71 greement with findings in the mouse model of invasive candidiasis, cph1/cph1 and efg1/efg1 C. albican

72 for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosa

73 For low prevalences of invasive candidiasis, culture-based fluconazole is reaso

74 inocandins are the recommended treatment for invasive candidiasis due to Candida glabrata.

75 iotics enhanced the susceptibility to murine invasive candidiasis due to impaired lymphocyte-dependen

76 mold infections, invasive aspergillosis, and invasive candidiasis during the first year after allogen

77 critically ill adults with risk factors for invasive candidiasis, empirical fluconazole did not clea

78 ole therapy is reasonable for likelihoods of invasive candidiasis greater than 2.5% or fluconazole re

79 tol concentrations in urine of patients with invasive candidiasis (>220 muM).

80 reased risk of mortality or of occurrence of invasive candidiasis (hazard ratio, 1.05; 95% confidence

81 the preemptive use of micafungin to prevent invasive candidiasis (IC) after abdominal surgery, the s

82 for intra-abdominal infection are at risk of invasive candidiasis (IC) and candidates for preemptive

83 lity to invasive fungal diseases (IFDs) like invasive candidiasis (IC) and invasive mold infections (

84 We characterized isolates from patients with invasive candidiasis (IC) breaking through >or=3 doses o

85 Delayed antifungal therapy for invasive candidiasis (IC) contributes to poor outcomes.

86 Rates of invasive candidiasis (IC) in children between 2003 and 2

87 Invasive candidiasis (IC) is an important cause of sepsi

88 Invasive candidiasis (IC) is an important healthcare-rel

89 Invasive candidiasis (IC) is associated with significant

90 sensitivity of blood cultures for diagnosing invasive candidiasis (IC) is poor.

91 Invasive candidiasis (IC) is the most common nosocomial

92 Neonatal invasive candidiasis (IC) presenting in the first week o

93 Diagnosis of invasive candidiasis (IC) relies on insensitive cultures

94 glucan (BG) levels with clinical outcomes in invasive candidiasis (IC) remains unknown.

95 The prevalence rate of invasive candidiasis (IC) was 11.4% (95% CI 9.2-13.6%),

96 andin for the treatment of candidemia and/or invasive candidiasis (IC) was noninferior to caspofungin

97 nce daily for treatment of candidemia and/or invasive candidiasis (IC).

98 infected with C. kefyr, with 8 (9.6%) having invasive candidiasis (IC).

99 (1,3)-beta-D-glucan (BG) is a biomarker for invasive candidiasis (IC).

100 gnostic strategies are needed for diagnosing invasive candidiasis (IC).

101 Rezzayo) for the treatment of candidemia and invasive candidiasis in adults with limited or no altern

102 le is recommended as first-line treatment in invasive candidiasis in children and infants.

103 ents to treat candidaemia and other forms of invasive candidiasis in human patients.

104 s, it has been considered as an indicator of invasive candidiasis in immunocompromised patients.

105 r the spectrum, risk factors, and outcome of invasive candidiasis in liver transplant recipients have

106 d and Drug Administration for prophylaxis of invasive candidiasis in patients undergoing bone marrow

107 Invasive candidiasis in premature infants causes death a

108 The incidence of proven/probable invasive candidiasis in the placebo and caspofungin arms

109 y means of a previously established model of invasive candidiasis in Toll mutant flies.

110 d mortality of fungal infections, especially invasive candidiasis, in patients in the intensive care

111 Some important advances in the diagnosis of invasive candidiasis include rapid species identificatio

112 CMC, invasive candidiasis, invasive aspergillosis, deep derma

113 Invasive candidiasis is a medical condition that is chal

114 Invasive candidiasis is a problem associated with substa

115 Invasive candidiasis is a serious infection in hospitali

116 Invasive candidiasis is an important fungal disease caus

117 Invasive candidiasis is an increasingly frequent cause o

118 ence of Candida albicans in a mouse model of invasive candidiasis is dependent on the phospholipids p

119 Mortality from invasive candidiasis is high.

120 Reduction in the incidence of invasive candidiasis is observed even when prophylaxis i

121 lized approach to diagnosis and treatment of invasive candidiasis is of paramount importance.

122 Invasive candidiasis is one of the most common nosocomia

123 Invasive candidiasis is the most common severe fungal in

124 Invasive candidiasis is the third most common bloodstrea

125 Species should be identified for invasive candidiasis isolates, and species-level identif

126 though candidemia is not always found during invasive candidiasis, it has been considered as an indic

127 Secondary and safety outcomes included invasive candidiasis, liver function, bacterial infectio

128 In individuals with invasive candidiasis, loss-of-function mutations in CARD

129 Centers with a low incidence of invasive candidiasis may not benefit from fluconazole pr

130 Documented invasive candidiasis occurred in 5% of fluconazole recip

131 Invasive candidiasis occurred less frequently in the flu

132 Invasive candidiasis occurs in the gastrointestinal trac

133 Tissue from 25 autopsy patients with invasive candidiasis of the gastrointestinal tract was s

134 utcome of any invasive fungal infections and invasive candidiasis or invasive aspergillosis (when pos

135 , a significant decrease in the incidence of invasive candidiasis (P=0.015), and an insignificant inc

136 as initial therapy in unstable patients with invasive candidiasis, particularly in the setting of pri

137 Invasive candidiasis poses a major healthcare threat.

138 a composite of death or definite or probable invasive candidiasis prior to study day 49 (1 week after

139 dose-dependent activity in a mouse model of invasive candidiasis, reducing kidney burden by three lo

140 of studies of caspofungin in candidaemia and invasive candidiasis suggest equivalent efficacy to amph

141 rkers that assess a patient's risk of having invasive candidiasis, tests will facilitate preemptive a

142 In treatment of murine invasive candidiasis, the concomitant or sequential use

143 Because candidemia is only one form of invasive candidiasis, the true burden of invasive infect

144 the risk that an individual will succumb to invasive candidiasis, the underlying mechanisms remain u

145 om relevant nonclinical models of candidemia/invasive candidiasis to inform the use of micafungin in

146 illion), and 3639037 visits occurred for non-invasive candidiasis (total cost $1.6 billion).

147 The epidemiology of invasive candidiasis varies in different geographical ar

148 the composite primary end point of death or invasive candidiasis was 16% (95% CI, 11%-22%) vs 21% in

149 sensitivity of a positive BG for identifying invasive candidiasis was 87%, with a 73% specificity.

150 The overall incidence of invasive candidiasis was increased in patients who recei

151 ll-validated pharmacodynamic murine model of invasive candidiasis, we defined the effect of the combi

152 e design of qPCR for the detection of deeply invasive candidiasis, we sought to develop a more compre

153 ive value, and negative predictive value for invasive candidiasis were 74%, 75%, 62%, and 84% in the

154 Patients who had invasive candidiasis were allowed to break the blind and

155 Five episodes of proven invasive candidiasis were documented in 4 patients; 1 of

156 d mycological confirmation of candidaemia or invasive candidiasis were eligible for inclusion and ran

157 consecutive liver transplant recipients with invasive candidiasis were prospectively studied in a cas

158 Adults with invasive candidiasis were randomly assigned to receive e

159 s intubated for at least 5 days, and free of invasive candidiasis, were included.

160 s safe and tended to reduce the incidence of invasive candidiasis when used for prophylaxis, but the

161 diagnosis of both invasive aspergillosis and invasive candidiasis, when interpreted in conjunction wi

162 e tests are limited by the low prevalence of invasive candidiasis, which mandates that results be int

163 cond, in critically ill patients at risk for invasive candidiasis who are non-neutropenic and are not

164 cond, in critically ill patients at risk for invasive candidiasis who are nonneutropenic and are not

165 The current standard of treatment of invasive candidiasis with echinocandins requires once-da

166 st common human nosocomial fungal infection, invasive candidiasis, yet the underlying mechanisms rema